Project Abstract

This project aims to thoroughly investigate the efficacy and safety of topical photodynamic therapy (PDT) as a treatment modality for actinic keratosis (AK), a precancerous skin condition that is commonly associated with chronic sun exposure. Actinic keratosis is a significant public health concern, as it can progress to squamous cell carcinoma, a type of skin cancer, if left untreated. The development of effective and well-tolerated treatment options is crucial for managing this condition and reducing the risk of cancer progression. Topical PDT is a promising approach that involves the application of a photosensitizing agent, such as 5-aminolevulinic acid (ALA) or methyl aminolevulinate (MAL), followed by exposure to a specific wavelength of light. This process triggers the generation of reactive oxygen species, which selectively target and destroy the abnormal actinic keratosis cells while minimizing damage to surrounding healthy skin. Previous studies have suggested that topical PDT may offer advantages over traditional treatments, such as improved cosmetic outcomes and better patient tolerability. The primary objective of this project is to conduct a comprehensive evaluation of the clinical efficacy and safety of topical PDT for the treatment of actinic keratosis. The study will involve a randomized, controlled trial, where participants with actinic keratosis will be randomly assigned to either the topical PDT treatment group or a control group receiving a standard therapy, such as cryotherapy or topical chemotherapy. The study participants will undergo a thorough assessment of their actinic keratosis lesions at baseline, followed by the administration of the topical photosensitizing agent and subsequent light exposure for the treatment group. The control group will receive the standard treatment as per the current clinical guidelines. Both groups will be monitored closely for the duration of the study, with regular evaluations of the lesions, assessment of clinical outcomes, and documentation of any adverse events. The primary outcome measure will be the complete clearance of actinic keratosis lesions at a pre-defined timepoint, such as 3 or 6 months after the initial treatment. Secondary outcomes will include the degree of lesion reduction, the time to lesion clearance, patient-reported outcomes (such as pain, cosmetic satisfaction, and quality of life), and the incidence of adverse events. The results of this study will provide valuable insights into the clinical efficacy and safety of topical PDT for the management of actinic keratosis. If the findings demonstrate the superiority of topical PDT over the standard treatments, it could lead to the establishment of this modality as a preferred option for clinicians and patients, potentially improving the overall outcomes and quality of life for individuals with actinic keratosis. Furthermore, the project will contribute to the broader understanding of the mechanisms underlying the therapeutic effects of topical PDT and help identify patient characteristics or lesion characteristics that may influence the treatment response. This knowledge can inform the optimization of treatment protocols and the development of more personalized approaches to managing actinic keratosis. Overall, this comprehensive evaluation of topical PDT for the treatment of actinic keratosis has the potential to significantly impact the clinical management of this common precancerous skin condition, ultimately enhancing patient outcomes and reducing the burden of skin cancer.

Project Overview